Company logo

DYN - Dyne Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Waltham, United States
Type: Equity

DYN price evolution
DYN
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Current assets
Cash $610.12 $273.95 $123.94 $132.6
Short term investments $170.64 $181.51 $1.47 $27.54
Net receivables
Inventory
Total current assets $792.32 $488.14 $129.38 $168.22
Long term investments
Property, plant & equipment $31.64 $32.22 $33.39 $34.7
Goodwill & intangible assets
Total noncurrent assets $33.56 $34.14 $35.71 $37.03
Total investments $170.64 $181.51 $1.47 $27.54
Total assets $825.88 $522.28 $165.08 $205.24
Current liabilities
Accounts payable $1.89 $7.21 $22.94 $3.55
Deferred revenue
Short long term debt $4.78 $4.76 $4.72 $4.71
Total current liabilities $29.75 $22.36 $51.09 $29.69
Long term debt $20.94 $21.86 $22.7 $23.51
Total noncurrent liabilities $20.94 $21.86 $22.7 $23.51
Total debt $25.72 $26.62 $27.41 $28.23
Total liabilities $50.69 $44.22 $73.79 $53.21
Shareholders' equity
Retained earnings -$763.26 -$698.16 -$632.51 -$565.87
Other shareholder equity -$0.24 -$0.13 -$0.01
Total shareholder equity $775.19 $478.06 $91.29 $152.04
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $123.94 $174.47 $200.82 $300.85
Short term investments $1.47 $83.86 $175.75 $44.46
Net receivables
Inventory
Total current assets $129.38 $265.59 $382.39 $349.09
Long term investments
Property, plant & equipment $33.39 $38.41 $40.96 $1.95
Goodwill & intangible assets
Total noncurrent assets $35.71 $40.73 $43.27 $4.25
Total investments $1.47 $83.86 $175.75 $44.46
Total assets $165.08 $306.32 $425.66 $353.33
Current liabilities
Accounts payable $22.94 $5.26 $4.03 $3.44
Deferred revenue
Short long term debt $4.72 $4.61 $3.89
Total current liabilities $51.09 $28.09 $28.72 $10.97
Long term debt $22.7 $25.87 $28.74
Total noncurrent liabilities $22.7 $25.87 $28.74
Total debt $27.41 $30.48 $32.64
Total liabilities $73.79 $53.96 $57.47 $10.97
Shareholders' equity
Retained earnings -$632.51 -$396.57 -$228.47 -$79.18
Other shareholder equity -$0.57 -$0.27 -$0.03
Total shareholder equity $91.29 $252.36 $368.2 $342.37
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $62.26 $44.54 $58.84 $55.25
Selling, general & administrative $9.7 $24.62 $8.84 $7.02
Total operating expenses $71.96 $69.16 $67.69 $62.27
Operating income -$71.96 -$69.16 -$67.69 -$62.27
Income from continuing operations
EBIT -$65.1 -$65.65 -$66.64 -$60.21
Income tax expense
Interest expense
Net income
Net income -$65.1 -$65.65 -$66.64 -$60.21
Income (for common shares) -$65.1 -$65.65 -$66.64 -$60.21
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $210.76 $142.76 $121.31 $45.2
Selling, general & administrative $31.4 $28.2 $28.72 $13.45
Total operating expenses $242.16 $170.96 $150.03 $58.65
Operating income -$242.16 -$170.96 -$150.03 -$58.65
Income from continuing operations
EBIT -$235.94 -$168.1 -$149.29 -$59.04
Income tax expense
Interest expense $0.4
Net income
Net income -$235.94 -$168.1 -$149.29 -$59.44
Income (for common shares) -$235.94 -$168.1 -$149.29 -$59.44
(in millions $) 30 Jun 2024 31 Mar 2024 31 Dec 2023 30 Sep 2023
Net income -$65.1 -$65.65 -$66.64 -$60.21
Operating activities
Depreciation $0.52 $0.56 $0.57 $0.6
Business acquisitions & disposals
Stock-based compensation $6.74 $19.91 $5.73 $4.88
Total cash flows from operations -$54.87 -$78.54 -$35.01 -$50.6
Investing activities
Capital expenditures -$0.86 -$0.19 -$0.08 -$0.17
Investments $12.03 -$179.65 $26.28 $12.99
Total cash flows from investing $11.17 -$179.84 $26.2 $12.82
Financing activities
Dividends paid
Sale and purchase of stock $379.86 $408.39 $0.15 $0.45
Net borrowings
Total cash flows from financing $379.86 $408.39 $0.15 $0.45
Effect of exchange rate
Change in cash and equivalents $336.17 $150.01 -$8.66 -$37.33
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$235.94 -$168.1 -$149.29 -$59.44
Operating activities
Depreciation $2.46 $3.35 $0.34 $0.7
Business acquisitions & disposals
Stock-based compensation $19.97 $15.18 $17.54 $6.59
Total cash flows from operations -$188.16 -$153.65 -$119.56 -$46.51
Investing activities
Capital expenditures -$0.73 -$3.07 -$3.62 -$1.16
Investments $84.04 $90.27 -$134.27 -$44.5
Total cash flows from investing $83.31 $87.2 -$137.89 -$45.66
Financing activities
Dividends paid
Sale and purchase of stock $54.32 $37.39 $157.82 $246.42
Net borrowings -$0.06
Total cash flows from financing $54.32 $37.39 $157.82 $380.69
Effect of exchange rate
Change in cash and equivalents -$50.52 -$29.05 -$99.63 $288.52
Fundamentals
Market cap $2.95B
Enterprise value $2.36B
Shares outstanding 100.12M
Revenue $0.00
EBITDA -$255.35M
EBIT -$257.60M
Net Income -$257.60M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -11.45
EV/Sales N/A
EV/EBITDA -9.26
EV/EBIT -9.18
P/S ratio N/A
P/B ratio 3.80
Book/Share 7.75
Cash/Share 6.09
EPS -$2.57
ROA -59.96%
ROE -68.85%
Debt/Equity 0.81
Net debt/EBITDA 2.19
Current ratio 26.63
Quick ratio 26.63